Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report.
作者信息
Schüller Hannah, Klein Franziska, Lübbert Michael, Prager Eric Peter
机构信息
Department of Nephrology, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Department of Hematology, Oncology & Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
出版信息
Ann Hematol. 2021 Mar;100(3):841-842. doi: 10.1007/s00277-020-04318-6. Epub 2020 Nov 10.
Abstract
摘要
相似文献
1
Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report.1例接受依库珠单抗治疗的阵发性睡眠性血红蛋白尿患者发生溶血性危机，可能由SARS-CoV-2（新冠病毒病）触发：病例报告
Ann Hematol. 2021 Mar;100(3):841-842. doi: 10.1007/s00277-020-04318-6. Epub 2020 Nov 10.
2
COVID-19 infection in patients on anti-complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience.接受抗补体治疗的患者感染新型冠状病毒肺炎：利兹国家阵发性夜间血红蛋白尿症服务经验
Br J Haematol. 2020 Oct;191(1):e1-e4. doi: 10.1111/bjh.17097. Epub 2020 Sep 18.
3
COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria.新冠病毒疫苗可在阵发性睡眠性血红蛋白尿症中引发严重溶血。
Blood. 2021 Jul 1;137(26):3670-3673. doi: 10.1182/blood.2021011548.
4
COVID-19 Presented with Deep Vein Thrombosis in a Patient with Paroxysmal Nocturnal Haemoglobinuria.COVID-19 合并阵发性睡眠性血红蛋白尿症患者发生深静脉血栓。
Hamostaseologie. 2021 Oct;41(5):397-399. doi: 10.1055/a-1554-6432. Epub 2021 Sep 20.
5
Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders.3例接受靶向C5补体的治疗性单克隆抗体治疗血液系统疾病的COVID-19患者的临床病程较轻。
Am J Case Rep. 2020 Sep 12;21:e927418. doi: 10.12659/AJCR.927418.
6
Effective eculizumab therapy followed by BMT in a boy with paroxysmal nocturnal hemoglobinuria.一名阵发性夜间血红蛋白尿男孩接受有效依库珠单抗治疗后进行骨髓移植。
Pediatr Int. 2015 Apr;57(2):e27-9. doi: 10.1111/ped.12522.
7
Terminal complement inhibition dampens the inflammation during COVID-19.终末补体抑制可减轻新冠病毒感染期间的炎症反应。
Br J Haematol. 2020 Aug;190(3):e141-e143. doi: 10.1111/bjh.16916. Epub 2020 Jun 28.
8
Severe COVID-19 infection in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab therapy.接受依库珠单抗治疗的阵发性夜间血红蛋白尿患者发生重症新型冠状病毒肺炎感染。
Leuk Lymphoma. 2021 Jun;62(6):1502-1505. doi: 10.1080/10428194.2020.1869963. Epub 2021 Jan 8.
9
Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.阵发性夜间血红蛋白尿患者长期使用依库珠单抗治疗后人体抗人抗体的评估。
Am J Hematol. 2016 Mar;91(3):E16-7. doi: 10.1002/ajh.24280.
10
Eculizumab therapy in paroxysmal nocturnal haemoglobinuria patient undergoing aortic valve surgery.接受主动脉瓣手术的阵发性夜间血红蛋白尿患者的依库珠单抗治疗。
Interact Cardiovasc Thorac Surg. 2019 Jun 1;28(6):994-995. doi: 10.1093/icvts/ivz020.
引用本文的文献
1
COVID-19 vaccination prevents a more severe course and treatment with complement inhibitors reduce worsening hemolysis during the Omicron pandemic in patients with PNH: a single-center study.COVID-19 疫苗接种可预防更严重的病情，在奥密克戎大流行期间，补体抑制剂治疗可减少 PNH 患者的溶血恶化：一项单中心研究。
Ann Med. 2023;55(2):2274510. doi: 10.1080/07853890.2023.2274510. Epub 2024 Jan 1.
2
Severe hemolytic exacerbations of Chinese PNH patients infected SARS-CoV-2 Omicron.中国 PNH 患者感染 SARS-CoV-2 奥密克戎后严重溶血加重。
Immun Inflamm Dis. 2023 Aug;11(8):e966. doi: 10.1002/iid3.966.
3
Complement and COVID-19: Three years on, what we know, what we don't know, and what we ought to know.补体与 COVID-19：三年过去了，我们知道了什么，不知道什么，以及我们应该知道什么。
Immunobiology. 2023 May;228(3):152393. doi: 10.1016/j.imbio.2023.152393. Epub 2023 May 11.
4
Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations.阵发性睡眠性血红蛋白尿症（PNH）中的补体抑制：中欧特殊患者人群的系统评价和专家意见。
Adv Ther. 2023 Jun;40(6):2752-2772. doi: 10.1007/s12325-023-02510-4. Epub 2023 Apr 18.
5
Breakthrough Hemolysis Associated With COVID-19 Vaccination and Active COVID-19 Infection in a Patient With Paroxysmal Nocturnal Hemoglobinuria Maintained on Pegcetacoplan: A Case Report.佩格西他单抗维持治疗的阵发性夜间血红蛋白尿患者中与新冠病毒疫苗接种及活动性新冠病毒感染相关的突破性溶血：一例报告
Cureus. 2023 Mar 16;15(3):e36240. doi: 10.7759/cureus.36240. eCollection 2023 Mar.
6
COVID-19 in Patients with Hematologic Diseases.血液系统疾病患者中的新型冠状病毒肺炎
Biomedicines. 2022 Nov 29;10(12):3069. doi: 10.3390/biomedicines10123069.
7
Pancytopenia in a Case of Aplastic Anaemia/Paroxysmal Nocturnal Haemoglobinuria Unmasked by SARS-CoV-2 Infection: A Case Report.SARS-CoV-2 感染导致再生障碍性贫血/阵发性睡眠性血红蛋白尿症患者全血细胞减少症：病例报告。
Medicina (Kaunas). 2022 Sep 15;58(9):1282. doi: 10.3390/medicina58091282.
8
Complement Mediated Hemolytic Anemias in the COVID-19 Era: Case Series and Review of the Literature.新型冠状病毒时代的补体介导溶血性贫血：病例系列及文献复习。
Front Immunol. 2021 Nov 25;12:791429. doi: 10.3389/fimmu.2021.791429. eCollection 2021.
9
COVID-19 infection presenting as paroxysmal nocturnal hemoglobinuria.表现为阵发性夜间血红蛋白尿的新型冠状病毒肺炎感染
Clin Case Rep. 2021 Aug 21;9(8):e04636. doi: 10.1002/ccr3.4636. eCollection 2021 Aug.
10
COVID-19 in patients with paroxysmal nocturnal haemoglobinuria: an Italian multicentre survey.阵发性睡眠性血红蛋白尿症患者中的新型冠状病毒肺炎：一项意大利多中心调查。
Br J Haematol. 2021 Sep;194(5):854-856. doi: 10.1111/bjh.17558. Epub 2021 May 25.
本文引用的文献
1
Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience.COVID-19 患者的依库珠单抗治疗：来自 ASL Napoli 2 Nord 真实经验的初步结果。
Eur Rev Med Pharmacol Sci. 2020 Apr;24(7):4040-4047. doi: 10.26355/eurrev_202004_20875.
Zotero 插件